Skip to main content
. 2018 Jun 1;9(42):26711–26723. doi: 10.18632/oncotarget.25475

Figure 2. Association of DNMT3B methylation with MRD, risk of relapse and EFS in multicenter AML02 cohort.

Figure 2

(A) Boxplot of DNMT3B methylation score by day 22 MRD status. (B) The cumulative incidence of risk of relapse and resistance disease (RR) in pediatric AML according to DNMT3B methylation score. (C) The cumulative incidence of event free survival (EFS) in pediatric AML according to DNMT3B methylation score.